Macular Degeneration supplements
Nutritional supplements play a role in slowing the progression of dry age-related macular degeneration (AMD) to late stage AMD.
MDeyes is Australia’s most affordable AREDS 2 capsule formula at $20.95 (RRP)
It delivers the complete AREDS 2 proven low zinc formula,including the specific quality ingredients FloraGLO Lutein and OPTISHARP Zeaxanthin,in a convenient once daily capsule.
Compliance Prompting Packaging with calendar labelling on the blister foils.
Grid printed on the back of each pack with blister sealed for optimum freshness
No added luten,dairy,sodium potassium salts,wheat,lactose, colours,flavours,preservatives.
Powder option mixes easily with water to avoid capsules
The new MDeyes Once Daily AREDS 2 powder contains the same complete, high quality AREDS 2 formula as the MDeyes capsules. Easily mixed with water for those who wish to avoid capsules or who have difficulty swallowing.
Including FloraGLO Lutein and OPTISHARP Zeaxanthin
Has a great-tasting natural orange flavor with no artificial colours, flavours or added sugar.
Includes a 4g scoop for dosage compliance and is affordably priced $29.95 (RRP) per tub (40 serves)
There has been significant progress in the treatment of neovascular AMD over the last few years following the development of anti-vascular endothelial growth factor (anti-VEGF) injections but there are potential benefits of antioxidant supplements in cases of dry ARM
Age-related macular degeneration is one of the leading causes of blindness and visual impairment in Australia and the Western world.
The exact mechanism by which this process occurs is not fully known but is largely thought to be multifactorial.
Age, genetics and exposure to both endogenous and environmental oxidative stress are factors
The original AREDS formula was developed in 2001 following a large, randomised, multicentre, double-masked and placebo-controlled clinical trial of 4,757 patients over a mean follow-up period of 6.3 years.
Follow up results of the AREDS study showed much data in reducing vision loss by the use of AREDS proven antioxidants
Subsequently, the AREDS2 Research Group was formed, which followed 4,203 patients as part of a multicentre, randomised, double-masked clinical and placebo controlled trial conducted over a five year period.
Lutein and zeaxanthin are found naturally concentrated within the macula and have both antioxidative and anti-inflammatory properties and are responsible for filtering out short wavelength blue light before it can reach the photoreceptors.
It has been shown that an increased dietary intake of lutein and zeaxanthin may be protective against development of late AMD but not early AMD.
Omega-3 long-chain polyunsaturated fatty acids and other particular acids have also been studied trying to improve the formula.
AREDS2 study group concluded particularly in patients with a history of smoking and/or a low dietary intake of lutein and zeaxanthin reducing beta-carotene to lutein/zexanthin as well as using a lower dose of zinc.
AREDS antioxidant supplements remain our most proven way of slowing progression to late stage AMD in high-risk patients.
The benefit of AREDS2 antioxidant supplements in dry cases and lifestyle modification such as cessation of smoking and performing light physical activity, as well as increasing dietary intake of omega-3 and carotenoids. Ideally a ‘Mediterranean diet’, which is rich in fish, nuts, vegetables, fruit and legumes, has been shown to be associated with lower incidences of AMD.
Some formulations in the market contain lower doses of the AREDS antioxidant ingredients.
Self-contained within individually dated blisters improves compliance.
The results of the large scale population based AREDS2 study strongly suggest that antioxidant and carotenoid supplements (but not necessarily omega-3 supplements) are indicated for patients at risk of progression to late stage AMD. Recent findings suggest the safety profile of these supplements is high.